These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7567767)

  • 1. ACE inhibitors in heart failure. What dose?
    Jolobe OM
    Postgrad Med J; 1995 Aug; 71(838):510. PubMed ID: 7567767
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure?
    Hobbs RE
    Cleve Clin J Med; 1998; 65(10):539-42. PubMed ID: 9830787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Asymptomatic cardiac insufficiency--therapy with ACE inhibitors. Wien, 4-5 December 1992. Abstracts].
    Wien Klin Wochenschr Suppl; 1992; 195():1-13. PubMed ID: 1363853
    [No Abstract]   [Full Text] [Related]  

  • 4. ACE inhibitors: who needs them?
    Heart Advis; 2007 Apr; 10(4):7. PubMed ID: 17494202
    [No Abstract]   [Full Text] [Related]  

  • 5. High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction?
    Pouleur H
    Cardiovasc Drugs Ther; 1993 Dec; 7(6):891-2. PubMed ID: 8011565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity of heart failure and dosage of angiotensin converting enzyme inhibitors.
    Clark AL; Coats AJ
    BMJ; 1995 Apr; 310(6985):973-4. PubMed ID: 7728033
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure.
    Hanon S; Vijayaraman P; Sonnenblick EH; Le Jemtel TH
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):147-50. PubMed ID: 11967806
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effective management of heart failure.
    Parmley WW
    Clin Cardiol; 1996 Mar; 19(3):240-2. PubMed ID: 8674263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor blockers: novel therapy for heart failure?
    Munger MA; Furniss SM
    Pharmacotherapy; 1996; 16(2 Pt 2):59S-68S. PubMed ID: 8668607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic cardiac insufficiency. Treatment with angiotensin I converting enzyme inhibitors and angiotensin II receptor antagonists].
    Juilliére Y; Berder V
    Presse Med; 2000 Apr; 29(13):743-8. PubMed ID: 10797830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underutilization of ACE inhibitors in older persons.
    Gillespie ND; Hutcheon S; McMurdo ME; Struthers AD
    J Am Geriatr Soc; 1999 Nov; 47(11):1385-6. PubMed ID: 10573456
    [No Abstract]   [Full Text] [Related]  

  • 13. [Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century].
    Gibelin P
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):41-5. PubMed ID: 11933555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients.
    Ahmed A; Allman RM; DeLong JF; Bodner EV; Howard G
    South Med J; 2002 Jul; 95(7):703-10. PubMed ID: 12144075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for chronic heart failure.
    Med Lett Drugs Ther; 1993 May; 35(896):40-2. PubMed ID: 8097552
    [No Abstract]   [Full Text] [Related]  

  • 16. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
    McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
    J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?
    Packer M
    J Am Coll Cardiol; 1996 Nov; 28(5):1323-7. PubMed ID: 8890833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
    Nicklas JM; Cohn JN; Pitt B
    J Card Fail; 2000 Jun; 6(2):165-8. PubMed ID: 10908091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.